How many stocks does BARCLAYS PLC own?

As of Q2 2024, BARCLAYS PLC holds 4,264 positions in their 13F portfolio.

What is BARCLAYS PLC's largest holding?

SPY at 14.7% of portfolio, worth $48.1M.

What is BARCLAYS PLC's total portfolio value?

$217.8B as of Q2 2024, tracked across 4,264 holdings.

Is BARCLAYS PLC a hedge fund?

BARCLAYS PLC is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does BARCLAYS PLC report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has BARCLAYS PLC's portfolio changed in Q2 2024?

View BARCLAYS PLC's latest portfolio changes, new positions, and exits for Q2 2024 on HoldingsIntel.

What is BARCLAYS PLC's investment strategy?

BARCLAYS PLC is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

BARCLAYS PLC Holdings Q4 2025 - Portfolio & Conviction Scores | HoldingsIntel

BARCLAYS PLC

Institutional investor · Portfolio as of Q2 2024

Solid(3.0 / 5.0)

$217.8B

AUM

4,264

Positions

252

New

Q2 2024

Filing Period

Quarterly Portfolio Change

SEC EDGAR SourceSEC Filings

BARCLAYS PLC manages $217.8B across 4264 positions as of Q2 2024. Top holdings: SPY (14.7%), QQQ (5.5%), MSFT (4.0%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.

Q2 2024 Summary

Active quarter - 252 new positions, 212 exits, 0 increased. Top move: NVDA (INCREASED, conviction 94). Portfolio: $217.8B across 4264 positions.

Portfolio Allocation

Top holdings by portfolio weight

SPY14.70%

QQQ5.52%

MSFT4.04%

NVDA3.85%

AAPL3.66%

IWM3.49%

AMZN2.26%

GOOGL1.78%

META1.56%

HYG1.10%

Other0.93%

Similar Funds

Funds with similar investing DNA

FEDERATED HERMES, INC.

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

VKTX23Q held

VIKING THERAPEUTICS INC

Avg $12.87 · $3.6M est. P&L

Est. P&L

+311.76%

ADMA23Q held

ADMA BIOLOGICS INC

Avg $2.85 · $1.5M est. P&L

Est. P&L

+291.90%

KNSA23Q held

KINIKSA PHARMACEUTICALS LTD

Avg $12.64 · $1.1M est. P&L

Est. P&L

+258.88%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings10 of 4808

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
SPY CALL Unit SPDR S&P 500 ETF TR	88.3M	$48.1M	14.7%	—	—	—	—	Increased —
QQQ CALL Unit INVESCO QQQ TR	37.7M	$18.1M	5.5%	—	—	—	—	Increased —
MSFT MICROSOFT CORP	29.6M	$13.2M	4.0%	—	$260.80	+69.48%	23 qtrssince 2018-Q4	Decreased 0
NVDA NVIDIA CORP	101.9M	$12.6M	3.8%	—	$116.05	+6.41%	23 qtrssince 2018-Q4	Increased 94
AAPL APPLE INC	56.8M	$12M	3.7%	—	$154.14	+35.59%	23 qtrssince 2018-Q4	Decreased 0
IWM CALL ETF ISHARES TR	56.2M	$11.4M	3.5%	—	—	—	—	Increased —
AMZN AMAZON COM INC	38.2M	$7.4M	2.3%	—	$127.82	+51.19%	23 qtrssince 2018-Q4	Decreased 0
GOOGL ALPHABET INC	31.9M	$5.8M	1.8%	—	$117.21	+54.41%	23 qtrssince 2018-Q4	Increased 51
META FACEBOOK INC	10.1M	$5.1M	1.6%	—	$283.33	+77.09%	23 qtrssince 2018-Q4	Increased 51
HYG CALL ETF ISHARES TR	46.5M	$3.6M	1.1%	—	—	—	—	Increased —
Showing 10 of 4,808 results.4,798 more with Pro.PROUpgrade to see all →